SCIENTIFIC EVIDENCE

Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp- untreated patients with advanced non-small cell lung cancer.

Thoracic cancer

Peng KC, Su JW, Xie Z, Wang HM, Fang MM, Li WF, Chen YQ, Guan XH, Su J, Yan HH, Zhang XC, Tu HY, Zhou Q, Chen HJ, Wu YL, Yang JJ.

Publication Overview

Key findings, Countstar context, and access to the original paper.

2022

3D Culture

Cancer Research

Organoid Culture

No items found.

Key Finding

Untreated EGFR-positive, MET-amplified lung cancer was associated with substantially shorter progression-free survival than EGFR-positive disease without MET amplification. First-line tyrosine kinase inhibitor monotherapy performed poorly, while dual-targeted therapy showed anticancer activity in the lung cancer organoid drug-testing assay.

Countstar Connection

Researchers assessed cell numbers in the study's cell samples using Countstar (model not specified) within the 3D-culture workflow for the cancer-model experiments.

Stay Connected to

Get new publications, application notes, cell analysis insights, and Countstar updates delivered to your inbox.

Meet us online